Targeted gene transfer to fetal rat lung interstitium by ultrasound-guided intrapulmonary injection by Henriques-Coelho, Tiago et al.
Targeted Gene Transfer to Fetal Rat Lung
Interstitium by Ultrasound-guided
Intrapulmonary Injection
Tiago Henriques-Coelho1,2,4, Sı́lvia Gonzaga1,3,4, Masayuki Endo1, Philip W Zoltick1,
Marcus Davey1, Adelino F Leite-Moreira2, Jorge Correia-Pinto3 and Alan W Flake1
1The Center for Fetal Research, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 2Department of Physiology, Faculty
of Medicine, University of Porto, Porto, Portugal; 3Department of Development and Neophasia, Life and Health Sciences Research Institute (ICVS),
School of Health Sciences, University of Minho, Braga, Portugal
In utero gene transfer to the developing lung may
have clinical or research applications. In this study, we
developed a new method for specifically targeting the
fetal rat lung with adeno and lentiviral vectors encoding
the enhanced green fluorescence protein (EGFP) marker
gene at E15.5 using ultrasound biomicroscopy (UBM).
Survival rate, morphometric parameters, viral biodistri-
bution, and lung transduction efficiency were analyzed
and compared to the intra-amniotic route of admi-
nistration. Expression of EGFP started as early as 24
and 72 h after the injection of adenoviral and lentiviral
vectors, respectively. Both vectors transduced lung
parenchyma with gene expression limited to interstitial
cells of the injected region, in contrast to intra-amniotic
injection, which targeted the pulmonary epithelium.
Expression of EGFP was most intense at E18.5 and E21.5
for adenoviral and lentiviral vectors, respectively. In
contrast to lentivirus, adenoviral expression significantly
declined until final analysis at 1 week of age. This
study demonstrates the feasibility of targeting the fetal
rat lung interstitium with viral vectors under UBM
guidance during the pseudoglandular stage. This model
system may facilitate in vivo studies of dynamic lung
morphogenesis and could provide insight into the
efficacy of prenatal gene transfer strategies for treatment
of specific lung disorders.
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INTRODUCTION
Prenatal gene transfer may offer a number of unique biological
advantages relative to postnatal gene transfer.1–4 The relatively
high frequency and accessibility of stem cells and progenitors
and their rapid proliferation in the fetus may offer efficiency
advantages for stem-cell-targeted gene transfer. The low total
cell number in the fetus allows relatively high vector to target
cell ratios, allowing the use of small amounts of vector. The
immunologic immaturity of the early gestational fetus may
induce tolerance to vector-associated or transgene-encoded
proteins. Finally, in utero gene transfer has the potential to treat
a disease before its clinical manifestations. Advances in prenatal
diagnosis of genetic and congenital disorders with progressively
more sensitive techniques may increase opportunities for
consideration of prenatal gene therapy.5,6
The fetal lung is an attractive target organ for fetal gene
transfer. There are a number of genetic and acquired disorders
with peri- or postnatal pulmonary manifestations. These include
monogenetic diseases like cystic fibrosis7 or surfactant protein B
(SP-B) deficiency that would presumably require long-term
expression of the deficient or defective gene. However, there
are also abnormalities of lung growth, such as congenital
diaphragmatic hernia, or lung maturation, such as respiratory
distress syndrome of prematurity, that could potentially
benefit from strategies that achieve transient gene expression
in specific pulmonary distributions. Additionally, an important
advantage of the use of non-integrating viral vectors with
transient gene expression is the avoidance of many of the
current concerns regarding integrating vectors in the fetus,
i.e., insertional mutagenesis, developmental abnormalities, and
germline alteration. We therefore anticipate the future need for a
variety of lung-targeting strategies using different gene transfer
technologies to achieve optimal therapeutic results.
In this study, we describe a new method for the direct
injection of viral vectors into the rat fetal lung as early as
the pseudoglandular phase of lung development. Using
this technique, we assessed the efficiency and distribution of
transduction in the lung, the biodistribution of transduction,
and the toxicity of equine infectious anemia virus (EIAV) and
adenovirus vectors expressing the enhanced green fluorescence
protein (EGFP) marker gene after in utero injection. In addition,
we compare the direct injection technique to intra-amniotic
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injection with respect to the efficiency of lung transduction, and
organ, and cellular distribution.
RESULTS
The technique of ultrasound-guided injections
Ultrasound biomicroscopy (UBM) was used to scan the fetus to
identify the lung (Figure 1). E15.5 was the earliest stage that
we could perform in utero injections with a high survival rate
and with accurate targeting of the developing lung. At E13.5 and
E14.5, the lung bud was very difficult to visualize and mortality
was unacceptably high. Important technical components of this
procedure were the performance of a maternal laparotomy to
expose the gravid uterus, and the application of pre-warmed
sterile ultrasound gel over the uterus. This allowed manipulation
of the fetal position into the axial orientation, which we found
was the optimal plane for injection. The lung was best visualized
between the level of the cardiac apex and upper part of the liver.
Applying this imaging technique, we could inject small volumes
(25–350 nL) of a viral vector suspension into the fetal lung
parenchyma without any visually apparent injury to the lung or
fetus. Injection of larger volumes was associated with the
disruption of fetal lung architecture. The fetus and micropipette
were manipulated so that the tip of the micropipette traversed
only the uterine wall, amniotic membrane, amniotic cavity, fetal
skin, and thoracic cavity (Figure 1 and Supplementary Video
S1), avoiding the placenta, limbs, heart, or liver.
Safety of in utero gene transfer
Viral vectors used in this study were first-generation adenoviral
vector and second-generation EIAV. To determine whether there
was inherent toxicity from the viral preparation or from the early
expression of the transgene, we compared survival after the
intrapulmonary injection of viral vectors with injection of an
equivalent volume of phosphate-buffered saline (PBS). The overall
survival rate was 8176, 8275, and 8774% for the PBS, EIAV,
and adeno groups, respectively. Survival rates were calculated per
dam by the formula: (number of injected fetuses alive/total
number of injected fetuses per dam) 100. There was no statistical
difference among the groups at the studied time points (Table 1).
In total, 53 dams were used and 527 fetuses were injected.
There were no maternal deaths. There was no evidence of
transplacental transfer of vector or transfected cells when
maternal blood was analyzed for EGFP by flow cytometry (data
not shown), although maternal tissues were not analyzed in
detail. Fetuses delivered by cesarean section or at term were
viable and without gross anomalies. Morphometric parameters,
namely body weight, lung-to-body and heart-to-body weight
ratios were similar and there were no statistical differences
among the groups (Table 1). Macroscopic structure of the lung
lobes, diaphragm, heart, and thoracic cavity was normal. Pups
Figure 1 Fetal lung injections guided by UBM. (a) The micropipette (mp) is aligned to target the fetal right lung (rl). (b) The micropipette
is advanced through uterine wall (u), and amniotic cavity (am) into the fetal lung; a small volume of viral vector suspension is injected into
the pulmonary parenchyma. Other organs can be clearly visualized: heart (h), liver (lv), left lung (ll), and spinal cord (sc). (c) After injection, the
micropipette is removed.
Table 1 Survival and somatic growth
PBS EIAV Adeno
E16.5
Survival (%) 8579 8277 78712
Body weight (g) 0.4970.02 0.5370.01 0.5170.02
Lung weight (mg) 1.8270.08 1.9870.04 1.7870.14
Heart weight (mg) 0.9470.07 0.8670.05 0.9870.8
E18.5
Survival (%) 9475 8776 8971
Body weight (g) 1.6070.04 1.7470.10 1.5270.09
Lung weight (mg) 3.1970.10 3.2770.12 3.2370.12
Heart weight (mg) 0.7570.04 0.6270.02 0.7270.05
E21.5
Survival (%) 72716 85710 9674
Body weight (g) 6.1070.24 5.8570.13 5.3570.10
Lung weight (mg) 2.5070.10 2.5670.10 2.6670.09
Heart weight (mg) 0.7670.06 0.6970.06 0.7770.02
P7
Survival (%) 72711 82712 8277
Body weight (g) 15.1970.13 14.0070.68 16.4370.64
Lung weight (mg) 2.2670.05 2.1570.08 2.2970.06
Heart weight (mg) 0.6770.01 0.7670.02 0.7070.02
EIAV, equine infectious anemia virus; PBS, phosphate-buffered saline. Survival is
presented as mean7SE of survival rate per dam calculated by the formula:
number of injected fetuses alive/total number of injected fetuses per dam100.
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that survived until the seventh day after birth displayed overtly
normal development and activity levels.
Efficiency of gene transfer to the lung and kinetics
of gene expression
To determine the overall pattern of gene expression, we used
stereoscopic fluorescence microscopy. After intrapulmonary injec-
tions, we observed that expression of EGFP, with the volumes of
injectate utilized, was almost entirely limited to the injected lung and
the ipsilateral pleural space after intrapulmonary injection (Table 2
and Figure 2). The time course of EGFP expression differed for the
two vectors. EGFP expression was detected as early as 24 h after
injection (E16.5) for adenoviral vector whereas the first expression
did not appear until 72 h after injection for the EIAV-derived
lentiviral vector (Figure 2). Maximum expression was observed at
E16.5–E18.5 for adenovirus and at E21.5–P7 for lentivirus. For
adenovirus, the intensity of lung EGFP fluorescence gradually
decreased until P7 when it was barely discernable. For EIAV at P7, the
intensity of the fluorescence was maintained, but the area of
fluorescence was smaller presumably owing to the growth of the
non-transduced lung and the relatively small area of initial
transduction. In the adenoviral group, expression of EGFP was also
seen in some fetuses in the skin and eyes, whereas in both groups the
contralateral non-injected lung was positive in a few fetuses (Table 2).
To confirm the fluorescence observations and to provide a
better quantitative assessment of changes in gene expression over
time in the injected lungs, we performed real-time polymerase
chain reaction (PCR) (Figure 3a). Evaluation of the number of
vector copies per lung revealed the presence of the vector at E16.5
in both EIAV and adenoviral groups. However, the number of
vector copies was statistically higher for adenoviral vector at E16.5
and E18.5. Whereas adenoviral-associated copy number progres-
sively decreased after E16.5, copy number from EIAV gene transfer
increased after E18.5 and was statistically greater than adenovirus
at P7. It is important to note that this is not a direct comparison
of transduction efficiency between the two viral vectors owing to
the differing volumes and titers injected. Approximately 25 nL of
adenoviral vector at a titer of 2–8 1011 i.p./mL was injected
versus 350 nL of EIAV vector at a titer of 108–109 i.p./mL. Thus,
even at the extremes of volume allowed by the model, there was at
least a 100-fold greater dose of adenoviral vector injected.
However, this quantitative data confirm the fluorescence observa-
tion of the rapid diminution in EGFP expression for adenoviral-
transduced lungs over the interval between E16.5 and P7. In
contrast, copy numbers, although relatively low, were maintained
in the EIAV group throughout the duration of the study.
Biodistribution of viral vectors
To confirm our impression that EGFP gene expression was
relatively limited to the lung after intraparenchymal injection
and to more globally assessed gene expression in the injected
fetuses, we performed quantitative PCR on several tissues at
E21.5 (Figure 3b). A statistically higher number of vector copies
relative to PBS controls were observed in the heart and in the
tract of the micropipette through the thoracic wall in both the
EIAV-EGFP and Adeno-EGFP groups. For all other tissues
analyzed, there were no statistical differences in EGFP expression
above the PBS-injected controls.
Cellular distribution of gene transduction within
the lung
EGFP-positive cells were predominantly found in the pulmonary
interstitium for both the EIAV and adenoviral groups, after
intrapulmonary injections (Figure 2i–p). There was no expres-
sion of reporter gene in the surface epithelium of airways or in
the vascular endothelium. EGFP-positive cells neither stained for
vimentin, a mesenchymal-derived cell marker (Figure 4a and b),
nor for SP-B, a surfactant protein expressed in Type II
pneumocytes (Figure 4c and d and Supplementary Figure
S2). Therefore, we demonstrated that transduced cells were
located within the interstitial compartment of the lung and that
they were not epithelial. This is in distinct contrast to the
epithelial-restricted expression seen with intra-amniotic vector
injections (Figure 4e and f).
DISCUSSION
We report for the first time, the feasibility of using UBM to
perform in utero intrapulmonary injections in rats at the
pseudoglandular stage of lung development. Both adenoviral
and lentiviral vectors efficiently transduced lung parenchyma,
although different expression patterns were observed following
Table 2 Viral vector biodistribution by fluorescence stereomicroscopy
E16.5 E18.5 E21.5 P7
EIAV Adeno EIAV Adeno EIAV Adeno EIAV Adeno
n injected 14 20 31 24 22 26 19 23
Lung injecteda
 7 1 2 1 1 0 1 0
+ 5 1 18 3 11 11 5 12
++ 1 8 8 10 8 13 10 10
+++ 1 10 3 11 2 2 3 1
Lung non-injected 0 2 1 4 4 4 1 0
Brain 0 0 0 0 0 0 0 0
Diaphragm 0 0 0 0 0 0 0 0
Eye 0 6 0 5 0 9 0 2
Gonads 0 0 0 0 0 0 0 0
Heart 0 0 0 1 0 0 0 0
Intestine 0 0 0 0 0 0 0 0
Kidney 0 0 0 0 0 0 0 0
Liver 0 0 0 0 0 0 0 0
Muscle 0 0 0 0 0 0 0 0
Skin 0 2 0 3 0 4 1 0
Spleen 0 0 0 0 0 0 0 0
Stomach 0 0 0 0 0 0 0 0
Trachea 0 0 0 0 0 0 0 0
EGFP, enhanced green fluorescence protein; EIAV, equine infectious anemia
virus. aNumbers represent the number of injected lungs that were negative or
positive for EGFP fluorescence at the time points stated. Positive animals were
subjectively ranked on a scale of + to +++ for intensity of fluorescence.
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injection. As expected, adenoviral vector expression appeared
quickly and was transient, whereas lentiviral vector expression
was relatively delayed and persisted through the time period of
this study. Unexpectedly, in contrast to intra-amniotic injections,
both vectors selectively transduced interstitial cells and not
alveolar or airway epithelial cells, or vascular endothelial cells.
Several routes of vector administration have been utilized
to achieve prenatal gene transfer to the lung including intra-
amniotic,8–11 systemic,12–14 intratracheal,15–17 and intrapulmon-
ary.18,19 Intra-amniotic and systemic approaches share the same
limitations of being nonspecific for fetal lung. Intratracheal and
intrapulmonary delivery, although more specific to the lung,
Figure 2 Fluorescence stereomicroscopy and lung immunostaining for EGFP. Injected fetuses at E15.5 were analyzed at E16.5, E18.5, E21.5, and
P7. Representative examples of fluorescence stereomicroscopy of the lungs at each analysis time after injection with (a–d) lentiviral vector and (e–h)
adenoviral vector are shown. Viral vector transduction can be detected by green fluorescence in an area around the location of the injection.
Representative images of immunostaining for EGFP from the lungs injected with (i–l) lentiviral vector and (m–p) adenoviral vector at the same analysis
times are presented. (i–l) Lentiviral vector was only detected at (j) E18.5, with more EGFP expression being detected at (k) E21.5 and maintained until
(l) P7. (m–p) Adenoviral vector induced an earlier expression of EGFP with maximal expression at (m, n) E16.5–E18.5. EGFP expression was analyzed
by immunoperoxidase (brown staining) and both vectors were expressed in interstitial cells. No epithelial expression was detected. Bar¼50 mm.
Figure 3 Quantitative PCR for EGFP. (a) Number of vector copies detected by quantitative PCR in lung samples after PBS, adenoviral, and lentiviral
injections, at different time points of gestation. (b) Number of vector copies detected by quantitative PCR in non-pulmonary tissues and non-injected
lung samples after PBS, adenoviral, and lentiviral injections at E21.5. Lv, liver; B, brain; St, stomach; Sp, spleen; I, intestine; M, muscle; K, kidney; H,
heart; Tx, thorax; Tr, trachea; D, diaphragm; E, eye; G, gonads; Sk, skin; niL, non-injected lung of injected fetuses. *Significant differences¼ Pp0.05
compared to PBS control.
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have previously only been performed in large animal models.
Tarantal et al.18 demonstrated, in a non-human primate model,
that intrapulmonary injections during the pseudoglandular stage
allowed specific targeting of the lung relative to injections
performed during the embryonic stage. In this study, we used
UBM to perform in utero intrapulmonary injections. The use of
this relatively new imaging technology made injection of the fetal
rat lung at E15.5. UBM utilizes high-frequency (20–100 MHz),
pulse-echo ultrasound for imaging live tissues and organs,
allowing near microscopic resolution and has been previously
utilized for fetal brain injections.20,21 Using UBM, we could
successfully target the rat lung during the mid-point of the
pseudoglandular stage of lung development with a high fetal
survival rate.
First-generation adenovirus and EIAV lentivirus-based vec-
tors were used in this study. We chose to study first-generation
adenoviral vectors rather than adeno-associated viral vectors
because we wished to see rapid, high-level expression of the
marker gene. We used EIAV owing to the fact that human
immunodeficiency virus-1-based lentiviral vectors have not
shown high efficiency transduction22,23 in many tissues and
owing to the successful application of EAIV vectors in fetal
rodent models by Waddington et al.14 Adenovirus has been one
of the most extensively studied recombinant viral systems
because of its high transduction efficiency, rapid expression,
accommodation of large transgene inserts, and high titers.23–26
The primary problem with adenovirus is its high immunogeni-
city and propensity to invoke strong immune responses. We
previously documented that this is a problem with intratracheal
administration in late gestational fetal lambs; however, in the
same model, no significant inflammation is observed with
adenoviral administration during the preimmune phase of lamb
immunologic development.27 Similarly, as we would predict
from the stage of rat immune development at E15.5, we saw
no overt inflammatory response in the lung by histology in
these experiments. However, as the purpose of this study was
not induction of immune tolerance, we did not perform a
detailed analysis of immune response to adenoviral products or
transgene. In contrast to adenovirus, lentiviral vectors are
relatively non-toxic and minimally immunogenic and can stably
integrate transgene into dividing and non-dividing cells with
subsequent long-term gene expression.28–30 The main disadvan-
tages are the low titers that are usually obtained in vitro.23 This
proved somewhat limiting in the current study. With EIAV
vector titers of only 107–108 infectious particles per mL, we
needed to inject the maximal tolerated volume of 350 nL of EIAV
to achieve significant transduction.
The rapid loss of EGFP expression in the adenoviral-
transduced lungs is in keeping with the known episomal location
of adenoviral gene expression, the small volume of vector
administered (25 nL), and the rapid proliferation of fetal lung
tissue. Our data are also consistent with the known capacity of
EIAV to stably integrate transgene into the host genome. In the
EIAV-transduced lungs, there was, if anything, a slight increase in
copy number at P7. We would conclude from this analysis that
adenovirus would be the most appropriate vector to use when
the goal is to induce rapid and transient overexpression of a gene
in this model, whereas, lentivirus would be a more suitable
vector to induce sustained and long-term gene expression.
Gene transfer was localized to the injected lung with the only
exceptions being the needle track through the thorax and a very
low copy number in the heart. This could be due to inadvertent
injection of the heart but is more likely due to the small amount
of intravascular injection associated with this technique. A few
animals had EGFP expression noted by stereoscopic fluorescent
analysis in the skin or eye. However, in the animals selected for
PCR analysis, these tissues did not have statistically higher gene
copy numbers than PBS controls. This discrepancy likely
represents inconsistent amounts of leakage of the vector into
the amniotic space during removal of the micropipette. The
lack of pulmonary epithelial transduction in these animals
despite intra-amniotic leakage is most likely explained by the
very minimal volume of leakage into the amniotic space relative
to the volume of injectate in the intra-amniotic injection
Figure 4 Interstitial localization of tranduced cells after intrapar-
enchymal injection. (a, b) Lung double immunofluorescence for EGFP
(green) and vimentin (red) in fetuses injected with (a) lentiviral and
(b) adenoviral vectors. Lungs were harvested at P7. (c, d) Lung
immunoperoxidase staining for EGFP (brown) and immunofluorescence
for SP-B (green). Images represent an overlay of bright light and
fluorescent images at original magnification 60 and 40 for c and d,
respectively. Merged images were created with Adobe Photoshop
software and adjusted for brightness, contrast, and opacification to
allow optimal visualization of both markers (original images before
manipulation can be seen in Supplementary Figure S2). EGFP-
positive cells did not colocalize with vimentin, or SP-B, and were
localized within the interstitial region of the parenchyma. (e, f) Epithelial
localization of transduced cells after intra-amniotic injection. Intra-
amniotic injections were performed at E16.5 and the fetuses were
harvested at E21.5. (e) Fluorescence stereomicroscopy and (f) lung
immunostaining for EGFP are presented demonstrating the transduction
of only epithelial cells. Bar¼50 mm.
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experiments as well as the timing of the injection. In our
experience, and that of others,8 efficient transduction efficiency
of pulmonary epithelium after the intra-amniotic delivery of
vector is limited to a narrow gestational window related to the
onset of fetal respiratory movements. In this study, intrapul-
monary injections were performed 1 day before the time point
when efficient transduction to pulmonary epithelium is seen
after intra-amniotic injection.
One of the most interesting findings in our study was the
specificity for the interstitial compartment seen with both
the vectors utilized. There was no expression of reporter gene in
the surface epithelium of airways or in the vascular endo-
thelium. The obvious question is, what population of cells was
transduced? Unfortunately, we were not able to definitively
identify the cells in this study owing to a lack of specific markers
for cell types in the interstitium. Although we suspected that
the cells were mesenchymal in origin, they do not stain with
vimentin, a common mesenchymal and fibroblast marker.
Attempts to colocalize EGFP staining with SP-B, a surfactant
protein expressed in Type II pneumocytes, confirmed that the
transduced cells were not epithelial, and that they were located
within the interstitial compartment of the lung. This is in
distinct contrast to the epithelial restricted expression seen with
intra-amniotic vector injections. Although the obvious explana-
tion is the route of injection, the needle tip must traverse all
layers of lung parenchyma on insertion and withdrawal and
one would expect to see epithelial transduction as well. We do
not have an explanation for this observation but it was seen
consistent in all lungs examined and with both vectors utilized.
In contrast, in the two previous studies of direct lung
transduction in primates using human immunodeficiency
virus-1 lentiviral vectors,18–19 only epithelial expression was
described, so this appears to be a model-dependent observation.
Further characterization of the type of cells that were transduced
will require additional studies. Nevertheless, to our knowledge,
this is the first observation of this pattern of parenchymal
expression with any reports of prenatal lung gene transfer. The
observation of transduction of distinct cell populations within
the lung with different routes of transduction raises the
possibility of manipulating gene expression in specific and
separate cell populations within the developing lung. This may
have interesting applications toward understanding mesenchy-
mal epithelial inductive interactions during the pseudoglandular
phase of lung development.
The ability to achieve gene transfer by direct intrapulmonary
injection in a rat model provides a novel tool for the exploration
of potential therapeutic strategies for lung disorders and for
biological studies examining the effects of specific genes on lung
development. Obvious advantages of this technique include ease
of manipulation, minimal expense, and, if translatable to the
mouse, the availability of well-characterized murine models of
human lung diseases.31–33 Although this study was performed in
rats, we now also have preliminary experience with this approach
in murine fetuses with similar success (data not shown). Finally,
the possibility of targeting the lung during the pseudoglandular
stage may present unique experimental and, ultimately perhaps,
clinical opportunities. This stage, characterized by intense
branching morphogenesis, is the period of greatest overall
growth of the airways and vasculature of the fetal lung, and
corresponds to a stage of immunologic immaturity and thymic
processing of self-antigen. Therefore, gene transfer during this
period has the potential to have major effects on the key
elements of lung growth with minimal potential for detrimental
immune responses.
MATERIALS AND METHODS
All experimental protocols were approved by the Institutional Animal
Care and Use Committee at the Children’s Hospital of Philadelphia and
followed guidelines set forth in the National Institutes of Health Guide for
the Care and Use of Laboratory Animals.
Viral vector preparation. EIAV-derived lentivirus vector expresses the
EGFP reporter gene from an internal cytomegalovirus immediate-early
promoter. The packaging plasmid, pEV53, and the SIN EIAV transfer
vector34,35 were kindly provided by Dr Bruce A Bunnell (Tulane
University, New Orleans, LA). The plasmid pFL85, containing the EIAV
provirus,36 was kindly provided by Dr Robert Stephens (National
Cancer Institute, Frederick, MD). The transfer plasmid, pZEK-CMV-
eGFP, was reassembled retaining the left and right long terminal repeats
and the extended packaging was inserted after the left long terminal
repeat.37 All Woodchuck hepatitis virus sequences were removed and
replaced with the modified Woodchuck hepatitis post-transcriptional
regulatory element.38 Viral vector pseudotyped with the vesicular
stomatitus virus G-protein (VSV-G) envelope was generated by three
plasmid co-transfections in 293T cells as described previously.29 The
initial transfection conditions were: 18 mg pE2KEGFPþ 18 mg
CMVDR8.91þ 12 mg VSV-Gþ 96.9 mL 2 M CaCl2 þ 2.5 mM HEPES,
pH 7.3 up to a total volume of 780 mL added to 780mL of 2 HEPES
buffer solution (HeBS) (280 mM NaCl, 50 mM HEPES, 1.5 mM
Na2HPO4, pH 7.0). The lentivirus vector supernatants were concen-
trated by ultracentrifugation at 28,000 r.p.m. for 90 min at 41C (SW-28
rotor, Beckman, Palo Alto, CA). Titers were determined by plaque-
forming assay. Vector particle titers obtained range from approximately
1 108 to 1 109 infectious particles per mL.
The E1–E3 replication-deficient recombinant adenovirus, based on
human serotype 5, contains eGFP under the human cytomegalovirus
immediate-early promoter (rAd-CMV-eGFP) and was obtained from
the vector core facility of the Gene Therapy Program (Division of
Medical Genetics, University of Pennsylvania, Philadelphia, PA).13
Recombinant vectors were prepared as previously reported.39–41
Adenoviral vector was stored at 801C in PBS with 5% glycerol. Before
administration, vector aliquots were resuspended in fresh PBS at a
concentration of 2–8 1011 infectious particles per mL.
Viral vectors administration. Ultrasound-guided injections. Time-dated
pregnant Sprague–Dawley rats (Charles-River, Wilmington, MA) at 15.5
days post coitum (E15.5) were anesthetized with isoflurane (3.5% for
induction, 2% for maintenance) and laid supine on a platform. The
body temperature was monitored via a rectal probe (Indus Instruments,
Houston, TX) and maintained at 36–381C. The surgical site was
chemically depilated and disinfected. A 2-cm ventral midline incision
was made and the uterus containing one or two fetuses was partially
exposed and covered with a pre-warmed sterile ultrasound gel
(Aquasonic, Parker Laboratories, Fairfield, NJ). Fetuses were positioned
to obtain axial views of the lungs in B-mode using a 40 MHz probe
(VisualSonics Vevo 660, Toronto, Canada). Glass microcapillary pipettes
(outer diameter 1.14 mm, inner diameter 0.53 mm, Humagen, Marlton,
NJ) were backfilled with mineral oil (Sigma, St Louis, MO), connected
to the micropipette holder that was attached to a three-axis micro-
injector unit (VisualSonics Vevo 660), filled with the PBS or viral vector
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suspension (5 mL), and aligned with the scanhead. Under two-
dimensional imaging, the micropipette tip was physically advanced
through the uterine wall and amniotic cavity into the lung and a specific
volume was injected. The micropipette was then physically retracted and
the next fetus was positioned and the procedure was repeated. Between six
and 10 fetuses were injected per dam. The maximum time of the surgical
procedure (between maternal abdominal incision and its closure) was
60 min. The abdomen was closed and dams recovered in a warming
chamber. Fetuses were harvested at E16.5, E18.5, E21.5 (by cesarean), and
P7. Fetuses or pups were inspected for the presence of macroscopic
abnormalities and body, wet lung, and heart weights were recorded.
Tissue samples were collected for histological and PCR analysis.
Intra-amniotic microinjections. Time-dated pregnant Sprague–Dawley
rats (Charles-River, Wilmington, MA) at 16.5 days post coitum (E16.5)
were anesthetized as described above. A midline laparotomy was made
and one horn of the uterus was exposed at a time. The injections were
performed under direct vision with glass microcapillary pipettes
connected to a microinjector. Pipettes were backfilled with adenovirus
suspension and 5mL were injected into the intra-amniotic cavity of each
fetus. Maximum time of the surgical procedure was 20 min. After
injections, the abdomen was closed in two layers and dams recovered in
a warming chamber. Fetuses were harvested at E21.5 (by cesarean) and
lungs were collected for analysis.
Fluorescence stereomicroscopy. Injected fetuses were visualized under
fluorescence stereomicroscopy (MZ16FA, Leica, Heerburgg, Switzer-
land) immediately after harvesting, to evaluate EGFP expression,
transduction efficiency, and biodistribution of the vector. After removal
of the fetus from the amniotic sac, the eyes and skin were inspected for
fluorescence. Thoracotomy was performed and the heart and lungs were
visualized. The liver, spleen, stomach, intestines, kidneys gonads, brain,
and muscles of the lower limbs were also inspected.
Histology and immunohistochemistry. Tissue specimens collected for
histology and immunohistochemistry were fixed in 10% buffered
formalin, embedded in paraffin, and stained with hematoxylin and
eosin. To evaluate and localize EGFP protein in the harvested lungs,
4mm serial sections were rehydrated and placed in 1% sodium
borohydride in PBS. Slides were blocked for specific protein with goat
serum (1:10 dilution) and incubated with monoclonal rabbit anti-GFP
IgG fraction (1:200 dilution; Molecular Probes, Eugene, OR). Slides were
then blocked for peroxidase with Dakocytomation (S-2001; Dako,
Carpenteria, CA) followed by incubation with biotinylated goat anti-
rabbit IgG (1:200 dilution; Vector Lab PK-4001, Burlingame, CA). Slides
were incubated with avidin–biotin complex (1:200 dilution; Vector Lab,
Burlingame, CA) developed with the peroxidase substrate kit (SK-4100;
Vector Lab, Burlingame, CA) and lightly stained with Harris
hematoxylin. For double immunofluorescence of GFP and vimentin,
slides were blocked with horse serum (1:10 dilution) followed by
incubation with monoclonal mouse anti-vimentin, Clone V9, M0725
(1:50 dilution; Dako, CA) at 41C and incubation with secondary
antibody Alexa Fluor A555 goat anti-mouse (1:100 dilution; Molecular
Probes, Eugene, OR). Slides were blocked with goat serum (1:10
dilution) followed by incubation with monoclonal rabbit anti-GFP IgG
fraction (1:200 dilution; Molecular Probes, Eugene, OR) at 41C and
incubation with secondary antibody Alexa Fluor A488 (1:200 dilution;
Molecular probes, Eugene, OR). Sections were coversliped with 40,60-
diamidino-2-phenylindole (Molecular Probes, Eugene, OR), visualized
under the microscope (Leica, DMRBE) to analyze the distribution of
GFP and the colocalization of GFP and vimentin (Iplab, Scientific
Imaging Software, BD Biosciences Bioimaging, Rockville, MD). Double
staining for GFP (immunoperoxidase) and SP-B (immunofluorescence)
was performed using the techniques described above. For SP-B, slides
were incubated with primary antibody (1:200 dilution, Chemicon,
Temecula, CA) followed by incubation with secondary antibody Alexa
Fluor A488 goat anti-rabbit (1:100 dilution, Molecular Probes, Eugene,
OR). Bright light microscopic and fluorescent images were then merged
to produce the images seen in Figure 4c and d.
Real-time PCR analysis. Samples from the injected lungs were collected
at E16.5, E18.5, E21.5, and P7. Extrapulmonary tissues were collected at
E21.5 and included the brain, diaphragm, eye, gonads, heart, intestine,
kidney, liver, muscle, skin, spleen, stomach, and trachea. All tissues
collected for PCR were immediately frozen in liquid nitrogen and stored
at 801C. Genomic DNA was isolated from tissues using the DNeasy
Tissue kit (Qiagen, Valencia, CA). Real-time PCR assays were performed
on the ABI PRISM 7900s Sequence Detection System. Sequence data
were obtained from the GenBank accession nos. U55763 for the cloning
vector pEGFP-C1 and NC005111 for Rattus norvegicus b-actin region of
chromosome 12. The internal probes of both TaqMan systems were
labelled at the 50 end with the reporter dye FAM (6-carboxyfluorescein)
and at the 30 end with the quencher dye TAMRA (6-carboxytetra-
methylrhodamine) (IDT, Coralville, IA). The primers and probe for
the pEGFP-C1 were as follows: forward 50-GGGCACAAGCTGGAGTA
CAACT-30; reverse 50-TCTGCTTGTCGGCCATGA-30; probe: 50-FAM-A
CAGCCACAACGTCT-TAMsp-30. The amplicon size was 61 bp. The
b-actin TaqMan system originated an amplicon with 92 bp and consisted
of primers and probe as follows: forward 50-GTATTCCTTTCTCTACA
GATCATG-30; reverse 50-CCAGAGGCATACAGGGACAAC-30; probe:
50-FAM-AGCCATGTACGTAGCCATCCAGGCTG-TAMsp-30. Amplifi-
cation conditions were identical for all reactions: 2 min at 501C,
10 min at 951C, 40 cycles at 951C for 15 s, and 601C for 1 min. The
amplification reactions were set in a final volume of 20 mL, containing
1TaqMan Universal PCR Mastermix (Applied Biosystems), 50 ng of
the gDNA sample, 900 nM of each primer, and 250 nM of the respective
probe. Negative control was included in all the runs. Standard
amplification curve for eGFP was made with pEGFP-C1, serially diluted
from 2 104 to 0.2 copies/mL. In all the samples, the calculated pEGFP
concentration was normalized for b-actin as internal control. For each
experimental group studied, three samples were analyzed in triplicate.
Amplification data were analyzed by the sequence detection system
software (SDS 1.2 version, Applied Biosystems).
Statistical analysis of data. The results were presented as mean7SEM.
To ascertain the statistical significance of the differences in the levels of
transduction in each tissue at different time points, one-way analysis of
variance was performed. Differences between groups were considered to
be statistically significant when Po0.05.
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SUPPLEMENTARY MATERIAL
Video S1. Fetal lung injections guided by UBM.
Figure S2. Fluorescent and bright light images of the merged images
in Figure 4c and d.
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